Drug Sales Trends for COMBIGAN

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for COMBIGAN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
COMBIGAN			2022
COMBIGAN			2021
COMBIGAN			2020
COMBIGAN			2019
COMBIGAN			2018

Market Analysis and Sales Projections for Combigan

Last updated: December 31, 2024

Introduction to Combigan

Combigan is a prescription eye drop approved for reducing elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. It is a fixed-dose combination product containing brimonidine tartrate 0.2% and timolol maleate 0.5%, developed and marketed by Allergan[4].

Market Context

The global glaucoma therapeutics market is experiencing significant growth, driven primarily by the increasing prevalence of glaucoma, particularly in aging populations. By 2027, the global glaucoma therapeutics market is projected to reach $11.05 billion, growing at a compound annual growth rate (CAGR) of 6.1% from 2019 to 2027[3].

Current Market Position

Combigan, approved in October 2007, is one of the key players in the glaucoma treatment market. It combines the efficacy of two older IOP agents, Alphagan (brimonidine tartrate) and Timoptic (timolol maleate), offering a two-pronged approach to reduce IOP. This combination has been shown to provide an additional IOP-lowering effect compared to the separate use of these drugs[4].

Sales Projections and Market Trends

Historical Performance

In the past, Combigan has been a significant contributor to the glaucoma treatment market. However, its sales have been influenced by various market dynamics. For instance, the introduction of new products and the loss of patent protection for existing drugs can impact sales.

Future Outlook

The glaucoma treatment market is expected to see sustained growth due to the introduction of new products and the increasing prevalence of glaucoma. However, Combigan's sales are anticipated to face challenges:

• Patent Expiration: Allergan will lose patent protection for Combigan (brimonidine and timolol) in 2022, which could lead to increased competition from generic versions and impact sales[1].
• Market Competition: The market will see the introduction of new fixed-dose combination (FDC) products, such as Roclatan (a prostaglandin analog-containing FDC), which is expected to achieve high sales and become a market driver[1].

Regional Performance

The United States is the dominant market for glaucoma treatments, and Combigan has a significant presence here. However, the overall market share of the U.S. is expected to rise slightly from 70.7% to 71.6% between 2013 and 2023, driven by the introduction of new products and an aging population[1].

Efficacy and Tolerability

Combigan's marketing strategy focuses on its efficacy and tolerability. Clinical studies have shown that Combigan, dosed twice daily, provides an additional IOP-lowering effect compared to the separate use of brimonidine and timolol. However, the IOP-lowering effect of Combigan is less than that seen with the concomitant administration of timolol and brimonidine at different dosing frequencies[4].

Adverse Reactions and Safety Profile

The most commonly observed adverse reactions associated with Combigan include somnolence and reduced alertness, particularly in pediatric patients using brimonidine tartrate as adjunctive therapy to beta-blockers[4].

Competitive Landscape

The glaucoma therapeutics market is highly competitive, with major players such as Novartis AG, Pfizer, Inc., and AbbVie Inc. The launch of new products by these market players is expected to drive the adoption of glaucoma therapeutics. For example, the introduction of Roclatan, a prostaglandin analog-containing FDC, is anticipated to generate significant sales and market share[3].

Key Takeaways

• Combigan's Role: Combigan is a significant player in the glaucoma treatment market, offering a fixed-dose combination of brimonidine and timolol.
• Market Growth: The global glaucoma therapeutics market is projected to grow at a CAGR of 6.1% from 2019 to 2027.
• Challenges: Combigan faces challenges from patent expiration and the introduction of new products.
• Regional Dominance: The U.S. dominates the glaucoma treatment market, with Combigan having a significant presence.
• Efficacy and Safety: Combigan is known for its efficacy and tolerability, though it has specific adverse reactions.

FAQs

1. What is Combigan used for? Combigan is used to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

2. What are the active ingredients in Combigan? Combigan contains brimonidine tartrate 0.2% and timolol maleate 0.5%.

3. When was Combigan approved? Combigan was approved on October 30, 2007.

4. What are the potential adverse reactions associated with Combigan? The most commonly observed adverse reactions include somnolence and reduced alertness.

5. How does Combigan compare to other glaucoma treatments? Combigan offers an additional IOP-lowering effect compared to the separate use of its components, but its efficacy can be less than concomitant administration of these drugs at different dosing frequencies.

Sources

1. Glaucoma Treatment Market Value Projected to Hit $3 Billion by 2023 - GlobalData
2. AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results - AbbVie
3. Glaucoma Therapeutics Market Growth, Share | Industry Report [2027] - Fortune Business Insights
4. Combigan - MM+M - Medical Marketing and Media
5. AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results - PR Newswire